Rapid antigen test and NAVICA mobile app designed to help restore a bit more confidence in daily life.
In this critical moment in the pandemic, testing is fundamental in our ability to help facilitate a return to work, school and life with a bit more confidence. BinaxNOW™ is a fast, reliable, affordable and portable rapid test that Abbott will produce at mass scale to greatly expand access to testing to people who need it. We'll ship tens of millions of tests in September, ramping production to 50 million tests a month in October.
We're pairing this $5, 15-minute, easy-to-use test with a mobile app, called NAVICA™, which works like a secure digital "boarding pass" that can be scanned to enter organizations and other places where people gather. This combination is life-changing technology that will attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability.
For U.S. residents, sign up to get notified when testing is available in your area.
Get the app before your first test.
Click here for product information on the BinaxNOW™ COVID-19 Ag Card and the NAVICA App.
BinaxNOW: With a swab & a card, reliable results in 15 minutes for coronavirus.
Chris Scoggins explains key features of BinaxNOW test + NAVICA app combo.
Fast. Affordable. Portable.
Comprehensive testing solution to help you feel more confident about your health.
With verified results, app's QR code can be digital pass for places people gather.
What is it, where you can get it and other answers to help you get started.
BinaxNOW and NAVICA are strong tools to help us get back to daily life.
Explaining the trade-offs between rapid antigen tests vs. lab-based tests.
Expert says a test with an app improves efficiency of communicating results.
The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.